China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

Chinese biopharmaceutical ​firm Innovent ‌Biologics and U.S. ​pharma ​giant Pfizer have ⁠struck a ​global ​licensing and collaboration deal worth ​up ​to $10.5 billion to ‌research ⁠and develop 12 early-stage ​cancer ​medicines, ⁠the companies ​said ​on ⁠Friday.